Abstract
Using monolayers of intestinal (Caco-2) cells as a model for studying inflammatory bowel disease (IBD), we previously showed that nuclear factor-κB (NF-κB) activation is required for oxidant-induced disruption of cytoskeletal and barrier integrity. Epidermal growth factor (EGF) stabilizes the F-actin cytoskeleton and protects against oxidant damage, but the mechanism remains unclear. We hypothesized that the mechanism involves activation of phospholipase C-γ (PLC-γ), which prevents NF-κB activation and the consequences of this activation, namely, cytoskeletal and barrier disruption. We studied wild-type and transfected cells. The latter were transfected with varying levels (1-5 μg) of cDNA to either stably overexpress PLC-γ or to inhibit its activation. Cells were pretreated with EGF before exposure to oxidant (H2O2). Stably overexpressing PLC-γ (+2.0-fold) or preincubating with EGF protected against oxidant injury as indicated by 1) decreases in several NF-κB-related variables [NF-κB (p50/p65 subunit) nuclear translocation, NF-κB subunit activity, inhibitory-κBα (I-κBα) phosphorylation and degradation]; 2) increases in F-actin and decreases in G-actin; 3) stabilization of the actin cytoskeletal architecture; and 4) enhancement of barrier function. Overexpression induced inactivation of NF-κB was potentiated by EGF. PLC-γ was found mostly in membrane and cytoskeletal fractions (<9% in the cytosolic fractions), indicating its activation. Dominant negative inhibition of endogenous PLC-γ (-99%) substantially prevented all measures of EGF protection against NF-κB activation. We concluded 1) EGF protects against oxidant-induced barrier disruption through PLC-γ activation, which inactivates NF-κB; 2) Activation of PLC-γ by itself is protective against NF-κB activation; 3) the ability to modulate the dynamics of NF-κB/I-κ Bα is a novel mechanism not previously attributed to the PLC family of isoforms in cells; and 4) development of PLC-γ mimetics represents a possible new therapeutic strategy for IBD.
Footnotes
-
This work was supported in part by a grant from Rush University Medical Center, Department of Internal Medicine, and by two National Institutes of Health RO1 grants (NIDDK 60511 to A.B. and NIAAA 13745 to A.K.).
-
DOI: 10.1124/jpet.103.062232.
-
ABBREVIATIONS: GI, gastrointestinal; IBD, inflammatory bowel disease; NF-κB, nuclear factor-κB; I-κBα, inhibitory-κBα; EGF, epidermal growth factor; PLC-γ, phospholipase C-γ; DMEM, Dulbecco's modified Eagle's medium; SH, src homology; OD, optical density; PAGE, polyacrylamide gel electrophoresis; IP, inositol phosphates; ELISA, enzyme-linked immunosorbent assay; FSA, fluorescein sulfonic acid; EGF-R, epidermal growth factor-receptor; DAG, diacyl glycerol; PKC, protein kinase C; PLCz, dominant negative inhibition of PLC-γ.
- Received October 31, 2003.
- Accepted December 10, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|